Next Article in Journal
Pharmacological Blockade of PPARα Exacerbates Inflammatory Pain-Related Impairment of Spatial Memory in Rats
Next Article in Special Issue
BPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment
Previous Article in Journal
Ammonium Glycyrrhizinate Prevents Apoptosis and Mitochondrial Dysfunction Induced by High Glucose in SH-SY5Y Cell Line and Counteracts Neuropathic Pain in Streptozotocin-Induced Diabetic Mice
 
 
Article

Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension

1
Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
2
Department of Pathology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
3
Department of Surgery, Faculty of Dental Medicine and Health, University of Osijek, 31000 Osijek, Croatia
4
Department of Anatomy and Neuroscience, School of Medicine, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia
*
Author to whom correspondence should be addressed.
Academic Editor: Mario Dell’Agli
Biomedicines 2021, 9(6), 609; https://doi.org/10.3390/biomedicines9060609
Received: 9 April 2021 / Revised: 17 May 2021 / Accepted: 18 May 2021 / Published: 26 May 2021
(This article belongs to the Special Issue Frontiers in Pentadecapeptide BPC 157)
Gastric pentadecapeptide BPC 157 therapy counteracts multiple organ dysfunction syndrome in rats, which have permanent occlusion of the superior mesenteric artery close to the abdominal aorta. Previously, when confronted with major vessel occlusion, its effect would rapidly activate collateral vessel pathways and resolve major venous occlusion syndromes (Pringle maneuver ischemia, reperfusion, Budd–Chiari syndrome) in rats. This would overwhelm superior mesenteric artery permanent occlusion, and result in local, peripheral, and central disturbances. Methods: Assessments, for 30 min (gross recording, angiography, ECG, pressure, microscopy, biochemistry, and oxidative stress), included the portal hypertension, caval hypertension, and aortal hypotension, and centrally, the superior sagittal sinus hypertension; systemic arterial and venous thrombosis; ECG disturbances; MDA-tissue increase; and multiple organ lesions and disturbances, including the heart, lung, liver, kidney, and gastrointestinal tract, in particular, as well as brain (cortex (cerebral, cerebellar), hypothalamus/thalamus, hippocampus). BPC 157 therapy (/kg, abdominal bath) (10 µg, 10 ng) was given for a 1-min ligation time. Results: BPC 157 rapidly recruits collateral vessels (inferior anterior pancreaticoduodenal artery and inferior mesenteric artery) that circumvent occlusion and ascertains blood flow distant from the occlusion in the superior mesenteric artery. Portal and caval hypertension, aortal hypotension, and, centrally, superior sagittal sinus hypertension were attenuated or eliminated, and ECG disturbances markedly mitigated. BPC 157 therapy almost annihilated venous and arterial thrombosis. Multiple organ lesions and disturbances (i.e., heart, lung, liver, and gastrointestinal tract, in particular, as well as brain) were largely attenuated. Conclusions: Rats with superior mesenteric artery occlusion may additionally undergo BPC 157 therapy as full counteraction of vascular occlusion-induced multiple organ dysfunction syndrome. View Full-Text
Keywords: BPC 157; superior mesenteric artery occlusion; vascular recruitment; rats BPC 157; superior mesenteric artery occlusion; vascular recruitment; rats
Show Figures

Figure 1

MDPI and ACS Style

Knezevic, M.; Gojkovic, S.; Krezic, I.; Zizek, H.; Malekinusic, D.; Vrdoljak, B.; Vranes, H.; Knezevic, T.; Barisic, I.; Horvat Pavlov, K.; Drmic, D.; Staroveski, M.; Djuzel, A.; Rajkovic, Z.; Kolak, T.; Kocman, I.; Lovric, E.; Milavic, M.; Sikiric, S.; Tvrdeic, A.; Patrlj, L.; Strbe, S.; Kokot, A.; Boban Blagaic, A.; Skrtic, A.; Seiwerth, S.; Sikiric, P. Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension. Biomedicines 2021, 9, 609. https://doi.org/10.3390/biomedicines9060609

AMA Style

Knezevic M, Gojkovic S, Krezic I, Zizek H, Malekinusic D, Vrdoljak B, Vranes H, Knezevic T, Barisic I, Horvat Pavlov K, Drmic D, Staroveski M, Djuzel A, Rajkovic Z, Kolak T, Kocman I, Lovric E, Milavic M, Sikiric S, Tvrdeic A, Patrlj L, Strbe S, Kokot A, Boban Blagaic A, Skrtic A, Seiwerth S, Sikiric P. Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension. Biomedicines. 2021; 9(6):609. https://doi.org/10.3390/biomedicines9060609

Chicago/Turabian Style

Knezevic, Mario, Slaven Gojkovic, Ivan Krezic, Helena Zizek, Dominik Malekinusic, Borna Vrdoljak, Hrvoje Vranes, Tamara Knezevic, Ivan Barisic, Katarina Horvat Pavlov, Domagoj Drmic, Miro Staroveski, Antonija Djuzel, Zoran Rajkovic, Toni Kolak, Ivica Kocman, Eva Lovric, Marija Milavic, Suncana Sikiric, Ante Tvrdeic, Leonardo Patrlj, Sanja Strbe, Antonio Kokot, Alenka Boban Blagaic, Anita Skrtic, Sven Seiwerth, and Predrag Sikiric. 2021. "Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension" Biomedicines 9, no. 6: 609. https://doi.org/10.3390/biomedicines9060609

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop